Related by context. All words. (Click for frequent words.) 74 small molecule inhibitor 73 orally bioavailable 72 PI3K inhibitor 72 multi kinase inhibitor 72 receptor tyrosine kinase inhibitor 72 HDAC inhibitor 71 small molecule inhibitors 71 tyrosine kinase inhibitor 71 kinase inhibitors 71 selective inhibitor 71 Hsp# inhibition 70 reversible inhibitor 70 histone deacetylase HDAC inhibitor 70 investigational humanized monoclonal antibody 70 Kinase Inhibitor 69 AKT inhibitor 69 Aurora kinase 69 protein kinase inhibitor 69 humanized monoclonal antibody 69 angiogenesis inhibitor 69 vascular disrupting agent 69 VEGFR2 69 ENMD # 69 MEK inhibitors 69 PI3K/mTOR 69 HCV protease 69 potent inhibitor 69 Hsp# inhibitors 69 HSP# inhibitor 69 MEK inhibitor 68 PDE4 inhibitor 68 selective kinase inhibitor 68 antisense oligonucleotide 68 IAP inhibitor 68 mTOR inhibitor 68 Fc fusion protein 68 polymerase inhibitor 68 CYC# 68 HDACi 68 FGFR 68 targeting CD# 67 kinase 67 signal transduction inhibitor 67 proteasome inhibitors 67 VEGF receptor 67 immunotherapeutic 67 PI3 kinase 67 HDAC 67 erlotinib Tarceva ® 67 PXD# 67 PNP inhibitor 67 PKC# 67 pertuzumab 67 small molecule tyrosine 67 JAK2 inhibitor 67 GRN#L 67 JAK1 67 HGS# 66 JAK inhibitor 66 deacetylase 66 Inhibitor 66 PI3K inhibitors 66 oral prodrug 66 histone deacetylase 66 Carfilzomib 66 molecularly targeted 66 multikinase inhibitor 66 PSN# [002] 66 PRT# 66 MLN# 66 pan HDAC inhibitor 66 Aurora kinase inhibitor 66 nucleoside analog 66 humanized anti 66 anti angiogenic 66 RGB # 66 isoform selective 66 highly selective inhibitor 66 xenograft models 66 novel peptide 66 potently inhibit 66 histone deacetylase inhibitors 66 sodium glucose cotransporter 66 anticancer agents 66 Preclinical studies suggest 66 proteasome inhibitor 66 BCR ABL 66 Factor VIIa 66 TLR8 agonist 65 liposomal formulation 65 vinca alkaloid 65 GMX# 65 enzyme inhibitor 65 FLT3 65 novel anticancer 65 SCH # 65 histone deacetylase inhibitor 65 HDAC Inhibitor 65 TLR8 65 poly ADP ribose polymerase 65 receptor antagonists 65 HCV protease inhibitor 65 hypoxia inducible factor 65 non nucleoside 65 small molecule 65 Tyrima 65 Hedgehog signaling pathway 65 AEG# 65 polymerase inhibitors 65 OXi# 65 Pertuzumab 65 otelixizumab 65 docetaxel Taxotere R 65 mTOR inhibitors 65 Annamycin 65 HDAC inhibitors 65 Hsp# inhibitor 65 selective agonist 65 selective antagonist 65 orally dosed 65 JAK2 inhibitors 65 M2 subunit 65 immunomodulatory 65 paclitaxel Taxol 65 sphingosine 1 65 kinase inhibition 65 BAY #-# 65 PARP inhibitor 65 inhibitor 65 selectively inhibits 65 Pathway Inhibitor 65 orally administered inhibitor 65 BRAF inhibitor 65 Nanobody ® 65 immunomodulator 65 generation purine nucleoside 65 RAF kinase 64 Kinase 64 CYT# potent vascular disrupting 64 cyclin dependent kinase inhibitor 64 irreversible inhibitor 64 IGF 1R 64 Blinatumomab 64 VEGFR 64 5 HT2A inverse 64 humanized antibody 64 antisense inhibitor 64 novel histone deacetylase 64 antitumor 64 Panzem NCD 64 PI3K 64 Janus Kinase 64 IAP inhibitors 64 ADP receptor antagonist 64 Panzem R 64 partial agonist 64 anti fibrotic 64 Guanilib 64 Nanobody 64 JAK inhibitors 64 cilengitide 64 immune stimulatory 64 selective inhibitors 64 depsipeptide 64 ENMD 64 Dasatinib 64 JAK2 64 targeted antifolate 64 imatinib Gleevec ® 64 Enzastaurin 64 tumor vascular disrupting 64 VEGF inhibitors 64 CTLA 4 64 cetuximab Erbitux R 64 PI3K/Akt pathway inhibitor 64 Sapacitabine 64 investigational compound 64 IgG1 monoclonal antibody 64 Squalamine 64 tyrosine kinase inhibitors 64 antibody fragment 64 obatoclax 64 dasatinib Sprycel 64 induces apoptosis 64 anticancer agent 64 pro apoptotic 64 small molecule activator 64 geldanamycin 63 OMP #R# 63 vascular disrupting agents 63 CA4P 63 serine protease 63 rNAPc2 63 systemic RNAi therapeutic 63 neratinib 63 CDK inhibitor 63 Pralatrexate 63 Cloretazine 63 anti angiogenic agent 63 alkylating agent 63 imetelstat 63 Factor Receptor 63 chemotherapeutic agent 63 peripherally acting 63 gamma secretase inhibitor 63 CD# antibody [001] 63 siRNA therapeutic 63 Syk 63 investigational oral 63 renin inhibitors 63 NS5A 63 induce apoptosis 63 Flt3 63 humanized monoclonal 63 targeted radiotherapeutic 63 ganetespib 63 potently inhibits 63 Gleevec resistant 63 epothilone 63 investigational monoclonal antibody 63 Pharmacokinetics PK 63 myeloproliferative disorders 63 5 HT6 63 epothilones 63 potent anticancer 63 deforolimus 63 Protein Kinase C 63 G Protein Coupled 63 MET VEGFR2 63 cyclin dependent kinases CDKs 63 Smac mimetics 63 PARP inhibitors 63 selective inhibition 63 FGFR1 63 phase IIb clinical 63 HER1 63 alpha folate receptor 63 OMP #M# 63 Beta catenin 63 Hsp# Inhibitor 63 HGS ETR1 63 peptibody 63 peptidomimetic 63 Debio 63 sorafenib Nexavar 63 Ceflatonin 63 NXL# 63 AP# [003] 63 DNA intercalator 63 Raf kinase 63 chimeric monoclonal antibody 63 Xanafide 63 BAL# [001] 63 Perifosine 63 immunomodulating 63 ALK inhibitor 63 antitumor activity 63 EGFR 63 Sorafenib 63 tubulin inhibitor 63 peptide antigens 63 PLX# 63 Voreloxin 63 NS4A 63 chemokine receptor 63 Denufosol 63 Mipomersen 63 oxidative stress inducer 63 topoisomerase II inhibitor 63 ATL# [001] 63 tyrosine kinase receptor 63 CD4 monoclonal antibody 62 VEGF receptors 62 PI3 Kinase 62 ErbB3 62 HuLuc# 62 potent antiproliferative 62 kinases 62 leukemia AML 62 aurora kinase inhibitor 62 EGFR inhibitors 62 seliciclib 62 MetMAb 62 AT1R 62 immunotoxin 62 bevacizumab Avastin ® 62 CCX# 62 selective estrogen receptor 62 chemokine 62 gemcitabine Gemzar ® 62 thrombin receptor 62 Survivin 62 XL# XL# 62 PEG SN# 62 Receptor Antagonist 62 sunitinib malate 62 Sym# 62 siRNA therapeutics 62 EGFr 62 drug conjugate 62 myelofibrosis polycythemia vera 62 fosbretabulin 62 Omacetaxine 62 potent inhibitors 62 vidofludimus 62 oral antiviral 62 selectively inhibit 62 MT# MEDI 62 oral kinase inhibitor 62 entinostat 62 Panzem R NCD 62 gefitinib Iressa 62 Bezielle 62 HGS ETR2 62 XL# [003] 62 elotuzumab 62 Angiolix 62 Vidofludimus 62 protein mTOR 62 immune modulating 62 mu opioid receptor antagonist 62 reslizumab 62 ErbB 62 vesicular monoamine transporter 62 receptor modulators 62 hormone LHRH antagonist 62 mertansine 62 anti CD3 62 GPCR targets 62 Curaxins 62 Aurora Kinase 62 axitinib 62 alvespimycin 62 multitargeted 62 tyrosine kinase 62 immunotherapeutic agent 62 survivin 62 somatostatin analogue 62 CD# monoclonal antibody 62 AZD# 62 Vorinostat 62 volociximab 62 hypoxia activated prodrug 62 ALN PCS 62 investigational antibody 62 PLK1 62 mitogen activated ERK kinase 62 specific protein tyrosine 62 LY# [002] 62 peroxisome proliferator activated 62 PDGF receptor 62 FOLOTYN ® 62 anticancer compound 62 Sphingomab 62 Phase Ib clinical 62 Bortezomib 62 novel orally administered 62 anti leukemic 62 protein kinase inhibitors 62 Liposomal 62 BMS # 62 receptor antagonist 62 dasatinib Sprycel ® 62 Dapagliflozin 62 selective orally bioavailable 62 IMA# 62 Tumor Necrosis Factor 62 phosphate S1P 62 #beta HSD1 62 bevacizumab Avastin R 62 nucleoside analogues 62 CCR9 62 lipopeptide 62 LY# [003] 62 VEGFR2 inhibitor 62 Interferon alpha 62 p# mitogen activated 62 bevacizumab Avastin 62 Luteinizing Hormone Releasing Hormone 62 adenoviral 62 telomerase inhibitor drug 62 Preclinical studies 62 eniluracil 62 antibody MT# 62 gemcitabine Gemzar 62 KSP inhibitor 62 Abl 61 EGFR HER2 61 CCR9 antagonist 61 antisense drug 61 JAK3 61 LHRH receptor positive 61 preclinical compounds 61 Olaparib 61 Janus kinase 61 Tarvacin TM 61 monoclonal antibody 61 c MET 61 HER3 61 ARRY # 61 aurora kinase 61 PCK# 61 TELINTRA 61 exon skipping 61 novel immunomodulatory 61 antisense inhibitors 61 P#X# 61 humanised antibody 61 PI3 K 61 Azixa 61 antibody MAb 61 pomalidomide 61 chemotherapeutic agents 61 IMC A# 61 CCR2 61 CCR5 antagonist 61 non nucleoside inhibitor 61 EGF receptor 61 ribonucleotide reductase 61 oncolytic 61 microtubule inhibitor 61 telomerase inhibitor 61 tyrosine kinase inhibitor TKI 61 Presents Preclinical Data 61 Zolinza 61 receptor agonist 61 histone deacetylase HDAC inhibitors 61 histone deacetylases 61 immune modulator 61 Seliciclib 61 cancer immunotherapies 61 mTOR mammalian target 61 factor G CSF 61 IMiDs R 61 AAG geldanamycin analog 61 angiotensin receptor blocker ARB 61 mGluR5 negative 61 TG# [001] 61 cytotoxic 61 seliciclib CYC# 61 preclinically 61 XL# XL# XL# 61 MET RET 61 immunomodulatory therapy 61 RDEA# 61 small molecule Hedgehog 61 Romidepsin 61 chemically modified siRNA 61 forodesine 61 Anticalin 61 Lenalidomide 61 cytoprotective 61 enzastaurin 61 Personalized Immunotherapy 61 5 HT2A receptor 61 PI3 kinase inhibitors 61 HCD# [002] 61 selective immunoproteasome inhibitor 61 Aplidin 61 metaglidasen 61 Deforolimus 61 histone deacetylase HDAC 61 p# inhibitor 61 SERMs 61 selective androgen receptor modulator 61 Pentraxin 2 61 Pazopanib 61 Phase Ib clinical trials 61 investigational pan BCR 61 demethylating agent 61 nucleoside 61 LHRH antagonists 61 PEP# [003] 61 Epratuzumab 61 gamma secretase inhibitors 61 subtype selective 61 metabotropic glutamate receptor 61 Vidaza azacitidine 61 glucagon receptor 61 investigational compounds 61 ARRY 61 AEZS 61 peptidic compound 61 Epothilones 61 VEGF Trap 61 protein kinases 61 agonist compounds 61 5 HT2A serotonin 61 GW# [003] 61 MUC1 61 luteinizing hormone releasing 61 Bruton tyrosine kinase 61 peptide conjugated 61 humanised monoclonal antibody 61 ON #.Na 61 ixabepilone 61 ErbB3 HER3 61 Ofatumumab 61 SAR# [002] 61 fusion protein 61 peripherally restricted 61 TRX1 61 antisense 61 solid tumors 61 TRC# 61 antisense oligonucleotides 61 LPA1 61 vemurafenib 61 bleomycin 61 anionic backbone 61 HCV polymerase 61 PDGFR 61 Chemokine Receptor 61 CEQ# 61 A3 adenosine receptor 61 Orally administered 61 Kinases 61 selectively binds 61 mediated apoptosis 61 long acting muscarinic 61 PTP 1B 61 2 methoxyestradiol 61 reverse transcriptase inhibitors 61 adenosine receptor 61 RNAi therapeutic targeting 60 Tanespimycin 60 therapeutic monoclonal antibody 60 sapacitabine 60 Hsp# chaperone system 60 bendamustine 60 personalized immunotherapy 60 investigational therapies 60 R roscovitine 60 S#P# 60 Cloretazine R 60 small molecule chemotherapeutic 60 pharmacodynamic profile 60 SGLT2 60 PI3K Akt 60 DB# [003] 60 HDAC inhibition 60 radiation sensitizer 60 modulator SERM 60 NPC 1C 60 cyclin dependent kinase 60 insulin sensitizing 60 THR beta agonist 60 nab paclitaxel 60 Imprime PGG 60 small molecule glucokinase 60 insulin sensitizer 60 Azedra 60 IMC #B 60 systemically administered 60 MAXY G# 60 tranilast 60 Pimavanserin 60 Maribavir 60 targeted tyrosine kinase 60 Factor VEGF 60 HER2 positive metastatic breast 60 relapsed ovarian cancer 60 bortezomib 60 trabectedin 60 glycogen synthase kinase 60 AMPK activators 60 selective modulator 60 oral proteasome inhibitor 60 protein tyrosine phosphatase 1B 60 registrational trial 60 Atrasentan 60 tumor vasculature 60 T DM1 60 IFN alpha 60 muscarinic 60 phosphoinositide 3 60 Panzem 60 hematological cancers 60 CRTH2 60 allosteric modulator 60 Imatinib 60 oral anticancer 60 generation proteasome inhibitor 60 XmAb ® 60 XmAb# 60 MGCD# [001] 60 ZD# [001] 60 corticosteroid dexamethasone 60 triphendiol 60 cyclin dependent kinase CDK 60 pro angiogenic 60 apoptosis proteins 60 gastrointestinal stromal tumors 60 reversible inhibitors 60 CR# vcMMAE 60 Daclizumab 60 SPC# [001] 60 apoptotic pathway 60 PEGylated Fab fragment 60 nucleoside reverse transcriptase inhibitor 60 elvitegravir 60 Herceptin trastuzumab 60 DU #b 60 hematologic malignancies 60 Smac mimetic 60 JAK3 inhibitor 60 TLR9 agonist 60 Aflibercept 60 c Raf kinase 60 antibody 60 potently inhibited 60 potent inhibition 60 insulin sensitizers 60 Amrubicin 60 integrase inhibitor 60 IgG1 antibody 60 small molecule agonists 60 Temsirolimus 60 TNF α 60 p# subunit 60 Vandetanib 60 PI3K/Akt pathway 60 CRAC channel 60 AQ4N 60 bispecific 60 Onconase 60 small molecule modulators 60 etoposide 60 phosphatidylinositol 3 60 Factor Xa 60 GLPG# 60 idarubicin 60 mitotic kinesin 60 Fibroblast Growth Factor Receptor 60 highly selective endothelin 60 retinoic acid receptor 60 HER2 antibody 60 subcutaneous formulation 60 CD3 monoclonal antibody 60 mTOR inhibition 60 intratumoral injection 60 bortezomib Velcade 60 CXCR4 60 virus HCV protease inhibitor 60 ErbB2 positive 60 cholesteryl ester transfer 60 DMAG 60 nicotinic acetylcholine receptor 60 2 inhibitor CYT# 60 ocular formulation 60 selective inverse agonist 60 predictive biomarker 60 5 HT4 receptor 60 PS# [001] 60 chemotherapeutic drug 60 TG# [003] 60 human monoclonal antibody 60 synthetic peptide 60 TMC# [002] 60 receptor inhibitor 60 rxRNA 60 TLR7 60 ISIS # 60 pan histone deacetylase 60 mda 7 60 YONDELIS 60 imatinib Gleevec 60 neuroprotectant 60 talabostat 60 transient receptor 60 angiogenesis inhibitors 60 alpha antagonist 60 developing Bicifadine serotonin 60 ara C 60 hematological malignancies 60 orally administered 60 Vascular Endothelial Growth 60 sunitinib Sutent ® 60 temsirolimus 60 antimitotic 60 elesclomol 60 Cytochrome P# 60 Angiotensin Converting Enzyme 60 castrate resistant prostate cancer 60 anticancer therapeutics 60 stable nucleic acid 60 tyrosine kinases 60 vorinostat 60 Cloretazine ® 60 MyVax R 60 lintuzumab 60 MTP inhibitor 60 E2F 60 TRV# [001] 60 Proxinium TM 60 HuMax EGFr 60 Ozarelix 60 Phase IIb clinical trials 60 RNA antagonist 60 daclizumab 60 binds selectively 60 Neulasta ® 60 peptidic 60 evaluating tivozanib 60 mTOR 60 Tarvacin 60 Thiarabine 60 IMiD 60 ASONEP 60 VEGF pathway 60 targeted kinase inhibitor 60 nitric oxide donating prostaglandin 60 milatuzumab 60 potentiator 60 Atiprimod 60 HDACs 60 huC# DM4 60 cediranib 60 MDM2 60 immunostimulatory 60 SAR# [004] 60 WT1 60 VAPRISOL 60 beta 1a 60 RH1 60 immune modulation 60 5 fluorouracil leucovorin 60 #ME# 60 FVIIa 60 Trastuzumab 60 thalidomide Thalomid 60 daunorubicin 60 ASG 5ME 60 vWF 60 hedgehog pathway 60 tubulin polymerization 59 anti CD# antibody 59 mGluR4 59 ALN TTR 59 mutational status 59 Elvitegravir 59 agonist 59 PF # [001] 59 Irinotecan 59 Tarceva TM 59 maturation inhibitor 59 tubulin binding 59 small molecule activators 59 adecatumumab MT# 59 antiproliferative 59 soluble receptor 59 regorafenib 59 NS5b 59 LEP ETU 59 novel VDA molecule 59 generation antisense 59 relapsed refractory multiple myeloma 59 delta isoform 59 proprietary polysaccharide 59 TLR agonists 59 BN# [002] 59 metastatic renal cell carcinoma 59 oncolytic viruses 59 Tumour Vascular Disrupting Agent 59 acetylcholinesterase 59 nicotinic alpha 7 59 small molecule thrombopoietin 59 histone methyltransferases HMTs 59 Posiphen 59 selective adenosine 59 varespladib 59 tipifarnib 59 taxanes 59 antimetastatic 59 diagnostic biomarker 59 DOS# 59 3 kinase PI3K 59 lapatinib Tykerb 59 Phase #b/#a clinical 59 BiTE 59 Erlotinib 59 XL# anticancer compounds 59 Bevacizumab 59 Litx 59 plasma kallikrein 59 fusion inhibitor 59 Talabostat 59 docetaxel Taxotere ® 59 topoisomerase 59 inhibiting tumor 59 Gemcitabine 59 AEGR 59 eprotirome 59 demonstrated antitumor activity 59 phosphorylate 59 Phase Ib study 59 cyclin dependent kinases 59 anticancer therapies 59 nanomolar range 59 E#F# 59 N acetylgalactosamine 6 59 NMDA antagonist 59 ascending doses 59 chronic lymphocytic leukemia CLL 59 BiTE antibody 59 Hedgehog pathway 59 cMET 59 Phase Ib 59 CD# [002] 59 antifolate 59 molecule epidermal 59 serine threonine kinase 59 multiple myeloma MM 59 CCR1 59 inverse agonist 59 TLK# 59 oral Azacitidine 59 VQD 59 Bcl 2 59 MGCD# [002] 59 anti proliferative 59 inhibitor RG# 59 LymphoStat B belimumab 59 thymidylate synthase TS 59 Exelixis XL# 59 brostallicin 59 Receptors GPCRs 59 neuronal nicotinic receptors NNRs 59 Interferon gamma 59 BiTE ® 59 Cylene 59 NFkB 59 selectively inhibiting 59 inhibit VEGF 59 estrogen receptor beta 59 receptor CXCR4 59 teriflunomide 59 CYT# 59 Archexin 59 PEGylated interferon 59 antithrombotic 59 Zybrestat 59 Symadex 59 Nexavar ® 59 anti secretory 59 DFMO 59 pharmacodynamic PD 59 intravesical instillation 59 enzyme inhibitors 59 IGF 1R inhibitor 59 renin inhibitor 59 trastuzumab Herceptin 59 Receptor Agonist 59 IL #E 59 predictive biomarkers 59 Tumor necrosis factor 59 interferon IFN 59 XL# inhibits 59 dexpramipexole 59 Imatinib mesylate 59 MKC# MKC# PP 59 lymphotoxin 59 factor receptor FGFR 59 kinase pathway 59 ERK pathway 59 DXL# 59 amrubicin 59 multicenter Phase II 59 essential thrombocythemia ET 59 Ixabepilone 59 Afatinib 59 TRAIL induced apoptosis 59 HIV integrase inhibitors 59 cytochrome P# 59 fluoropyrimidine 59 prodrug 59 Curaxin 59 investigational oral inhibitor 59 HCV polymerase inhibitor 59 ZACTIMA 59 vaccine GRNVAC1 59 Crizotinib 59 visilizumab 59 Phase Ib II 59 gamma secretase 59 gemcitabine 59 fibrinolytic 59 Galectin 59 methionine aminopeptidase 59 RAS MAPK pathway 59 myeloproliferative diseases 59 hepatocyte growth 59 IL# PE#QQR 59 receptor tyrosine kinase 59 epithelial tumors 59 CCR5 antagonists 59 Fleximer 59 mGluR2 NAM 59 sunitinib Sutent 59 FK# 59 generation Hsp# inhibitor 59 nucleoside analogue 59 polycythemia vera PV 59 Erbitux cetuximab 59 chemopreventive agent 59 crizotinib PF # 59 OncoVEX GM CSF 59 proto oncogene 59 mTOR pathway 59 Epidermal Growth Factor 59 antisense compounds 59 PSMA ADC 59 p# inhibitors 59 bispecific antibody 59 factor Xa 59 Quinamed 59 Vascular Disrupting Agent 59 TKB# 59 PDX pralatrexate 59 flavopiridol 59 MAPK pathway 59 triciribine phosphate monohydrate 59 V#F mutation 59 HCV NS5B polymerase 59 erlotinib Tarceva 59 intranasal formulation 59 decitabine 59 selective adhesion molecule 59 SU# [003] 59 gastrin 59 trans retinoic acid 59 direct thrombin inhibitor 59 topotecan 59 Bevirimat 59 extracellular domain 59 thyroid hormone receptor 59 antitumoral 59 T#I mutant 59 VEGF 59 GLP toxicology studies 59 androgen receptor AR 59 OncoVEX 59 dipeptidyl peptidase IV 59 bone metastasis 59 fusion proteins 59 bifunctional 59 PLK1 SNALP 59 injectable formulation 59 azoles 59 Adenosine 59 cetuximab Erbitux ® 59 chemotherapeutics 59 ARIKACE ™ 59 immune modulators 59 humanized monoclonal antibodies 59 Bevasiranib 59 lintuzumab SGN 59 Docetaxel 59 oral Janus kinase 59 Azacitidine 59 tumor xenograft models 59 IL 1ß 59 JAK2 Inhibitor 59 Stapled Peptide 59 therapeutic antibody 59 antisense inhibition 59 GM CSF 59 FGFR3 59 CDK cyclin dependent 59 superficial bladder cancer 59 cell lymphoma CTCL 59 oncology therapeutics 59 generation nucleoside analog 59 apoptosis inducers 59 glucocorticoid receptor 59 inhibits Akt activation 59 tkRNAi 59 anti apoptotic 59 generation antisense inhibitor 59 anti VEGF 59 disease modifying 59 #HT#A 59 Phase 2b clinical trials 59 prolyl hydroxylase inhibitors 59 TLR9 agonists 59 compound PMX # 59 Epidermal Growth Factor Receptor 59 anti angiogenic agents 59 EndoTAG TM -1 59 Sphingomab TM 58 Phase IIa trials 58 HCV NS3 protease 58 RANK ligand 58 oral JAK1 58 Goserelin 58 paclitaxel Taxol ® 58 protease inhibitor 58 mTOR kinase 58 neuroprotective properties